Glaukos

Traded on the St. Petersburg Stock Exchange
Glaukos is a glaucoma treatment company developing micro-bypass therapies to moderate the intraocular pressures that help preserve vision.
Glaukos stock price chart
+77%
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Glaukos balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Glaukos cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Glaukos multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Glaukos profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Glaukos assets
Glaukos cash flows

Glaukos shares

TickerNameTypeNominal valueISINPrice
GKOS:USGlaukos Corp.Common share-US3773221029$88.08
Glaukos news
05.05.2022
Net income of Glaukos under GAAP for the 3 months of 2022 amounted to $5.377 million, compared to a loss of $16.469 million in the previous year. Revenue decreased by 0.4% to $67.681 million from $67.968 million a year earlier.
23.02.2022
Glaukos' GAAP loss for 2021 was $49.593 million, down 2.4 times from $120.348 million in the previous year. Revenue increased 30.7% to $294.011 million from $224.959 million a year earlier.
05.11.2021
Glaukos' GAAP loss for 9M 2021 was $27.721 mln, down 3.9 times from $109.7 mln in the previous year. Revenue increased 45.5% to $220.771 million from $151.725 million a year earlier.
06.08.2021
Glaukos' GAAP loss for six months of 2021 was $33.951 million, down 2.8 times from $93.952 million in the previous year. Revenue increased 68.1% to $146.061 million from $86.894 million a year earlier.
General information
Company nameGlaukos
SectorHealth Care / Health Care Equipment & Services / Health Care Equipment & Supplies / Health Care Supplies
Business address229 AVENIDA FABRICANTE SAN CLEMENTE CA 92672 949-367-9600
Mailing address229 AVENIDA FABRICANTE SAN CLEMENTE CA 92672
Websitewww.glaukos.com
Information disclosurewww.sec.gov